First human test for Next-Gen chikungunya shot begins
NCT ID NCT07394426
Summary
This is an early-stage study testing a new experimental vaccine designed to prevent chikungunya virus infection. The study will enroll 40 healthy adults to check the vaccine's safety, side effects, and whether it triggers an immune response. Participants will receive two injections six weeks apart and will be monitored for over a year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHIKUNGUNYA VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.